PC
MTCR

PA Capital’s Metacrine, Inc. Common Stock MTCR Stock Holding History

PA Capital’s Portfolio MTCR Stock Details MTCR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$350K Buy
+34,280
New +$351K 0.25% 129

Other funds holding MTCR

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
VP
venBio Partners San Francisco, California $281M AUM 261.03% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
ACH
ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return

PA Capital's MTCR Position: Q3 2020 in Review

PA Capital opened a new position in Metacrine, Inc. Common Stock (MTCR) in Q3 2020: 34,280 shares worth $350K. The stake represents 0.25% of the portfolio and ranks #129 among its holdings.

26 funds tracked by Wall St. Rank hold MTCR as of Q3 2020.

  • PA Capital held 34,280 shares of Metacrine, Inc. Common Stock worth $350K as of Q3 2020.
  • Metacrine, Inc. Common Stock was a new PA Capital position in Q3 2020.
  • Metacrine, Inc. Common Stock made up 0.25% of PA Capital's portfolio in Q3 2020, its #129 holding.
  • 26 funds tracked by Wall St. Rank held Metacrine, Inc. Common Stock as of Q3 2020.

Based on PA Capital's 13F filing for Q3 2020, filed 13 Nov 2020.